PUBLISHER: The Business Research Company | PRODUCT CODE: 1957679
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957679
Post-marketing pharmacovigilance involves the ongoing monitoring of a drug's safety after it has been released on the market, aiming to detect, assess, and prevent adverse effects or other drug-related issues. Medical information services provide accurate, scientific, and up-to-date responses to healthcare providers and patients regarding a drug's use, safety, and efficacy. Together, these processes protect patient health, ensure regulatory compliance, and improve treatment outcomes.
The main types of post-marketing pharmacovigilance and medical information include spontaneous reporting, intensified adverse drug reaction (ADR) reporting, targeted spontaneous reporting, cohort event monitoring, and electronic health record (EHR) mining. Spontaneous reporting involves healthcare professionals or patients voluntarily identifying and reporting unexpected reactions linked to medication use to authorized organizations. It includes product formats such as books, online media, and journals, and serves a variety of end users, including hospitals, research organizations, and others.
Tariffs have impacted the post-marketing pharmacovigilance and medical information market by increasing costs of imported software solutions, analytical tools, and digital monitoring platforms. Segments like electronic health record (EHR) mining and real-time ADR monitoring systems are most affected, particularly in North America and Europe where imports are significant. This has led to increased operational costs and slower technology adoption. However, tariffs have encouraged local development of pharmacovigilance platforms, innovation in AI-based monitoring tools, and greater domestic investment in medical information services.
The post-marketing pharmacovigilance and medical information market research report is one of a series of new reports from The Business Research Company that provides post-marketing pharmacovigilance and medical information market statistics, including post-marketing pharmacovigilance and medical information industry global market size, regional shares, competitors with a post-marketing pharmacovigilance and medical information market share, detailed post-marketing pharmacovigilance and medical information market segments, market trends and opportunities, and any further data you may need to thrive in the post-marketing pharmacovigilance and medical information industry. This post-marketing pharmacovigilance and medical information market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The post-marketing pharmacovigilance and medical information market size has grown rapidly in recent years. It will grow from $6.9 billion in 2025 to $7.71 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to limited post-marketing surveillance infrastructure, reliance on manual ADR reporting, growing regulatory requirements for drug safety, increased number of new drug approvals, lack of integrated hospital data systems.
The post-marketing pharmacovigilance and medical information market size is expected to see rapid growth in the next few years. It will grow to $11.89 billion in 2030 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to integration of ai and ml algorithms in signal detection, adoption of longitudinal patient data analysis, expansion of disease registry-linked monitoring, increasing digital app-based reporting, rising investments in real-time pharmacovigilance technologies. Major trends in the forecast period include increasing adoption of electronic health record (ehr) mining, rising use of real-time adverse drug reaction (adr) monitoring systems, growth in risk population-based and therapeutic class-based reporting, expansion of cohort event monitoring for new drug users, integration of digital and mobile platforms for pharmacovigilance reporting.
The climbing rate of adverse drug reactions is set to accelerate the post-marketing pharmacovigilance and medical information market ahead. Adverse drug reactions are noxious or unplanned responses from drugs used at normal doses for prevention, diagnosis, or care. Their frequency grows with an aging populace managing multiple chronic issues via polypharmacy, amplifying risks of interactions and surprises. Post-marketing pharmacovigilance and medical information tackle these by spotting, logging, and disseminating post-launch side effect data to uphold drug safety and utility. For example, in January 2023, Navikenz, a US AI-driven IT services firm, estimated US adverse drug reactions claim 200,000-400,000 lives yearly-outpacing stroke and diabetes combined-with 2.7 million cases sparking over 100,000 hospital stays and 15,000+ deaths. Thus, the surging adverse drug reactions are propelling the post-marketing pharmacovigilance and medical information market.
Leading companies in the post-marketing pharmacovigilance and medical information market are advancing tools like AI-powered pharmacovigilance workflows to sharpen event spotting and deliver instant safety oversight for superior patient results. AI-powered pharmacovigilance workflows harness artificial intelligence for automated safety surveillance, hastening detection and bolstering compliance. For instance, in January 2024, PubHive Ltd., a UK cloud SaaS provider, rolled out centralized Summary of Product Characteristics (SmPC) management for life sciences and research. The system unifies vital safety data in one hub, automates lit scanning and reports, fosters collaboration, and eases rules via AI smarts-empowering teams for proactive, efficient ops that safeguard patients and meet regs.
In October 2023, Ergomed plc, a UK pharma services firm, bought Panacea Pharma Projects Limited for an undisclosed sum. This expands Ergomed's PrimeVigilance unit, amps capabilities, and widens reach to cement leadership in pharmacovigilance. Panacea Pharma Projects Limited is a UK consultancy expert in pharmacovigilance (PV) and medical info, including post-market aid.
Major companies operating in the post-marketing pharmacovigilance and medical information market are Accenture plc, Sanofi S.A., Capgemini SE, Merck & Co. Inc., Cognizant Technology Solutions Corporation, IQVIA Holdings Inc., HCL Technologies Limited, ICON plc, Syneos Health Inc., Genpact Limited, Parexel International Corporation, Avalere Health LLC, Quanticate Limited, Inizio Consulting LLC
North America was the largest region in the post-marketing pharmacovigilance and medical information market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-marketing pharmacovigilance and medical information market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the post-marketing pharmacovigilance and medical information market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The post-marketing pharmacovigilance and medical information market includes revenues earned by entities by providing services such as adverse event reporting and management, signal detection and risk assessment, drug safety database, medical call center services, and regulatory compliance support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Post-Marketing Pharmacovigilance And Medical Information Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses post-marketing pharmacovigilance and medical information market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for post-marketing pharmacovigilance and medical information ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The post-marketing pharmacovigilance and medical information market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.